Cargando…

Rethinking Lupus Nephritis Classification on a Molecular Level

The International Society of Nephrology/Renal Pathology Society (ISN/RPS) lupus nephritis (LN) classification is under reconsideration, given challenges with inter-rater reliability and resultant inconsistent relationship with treatment response. Integration of molecular classifiers into histologic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Almaani, Salem, Prokopec, Stephenie D., Zhang, Jianying, Yu, Lianbo, Avila-Casado, Carmen, Wither, Joan, Scholey, James W., Alberton, Valeria, Malvar, Ana, Parikh, Samir V., Boutros, Paul C., Rovin, Brad H., Reich, Heather N.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6832959/ https://www.ncbi.nlm.nih.gov/pubmed/31547518 http://dx.doi.org/10.3390/jcm8101524

Ejemplares similares

Molecular characterization of proliferative lupus nephritis
por: Parikh, Samir V, et al.
Publicado: (2014)

Characterising the immune profile of the kidney biopsy at lupus nephritis flare differentiates early treatment responders from non-responders
por: Parikh, Samir V, et al.
Publicado: (2015)

Identification of a neutrophil-related gene expression signature that is enriched in adult systemic lupus erythematosus patients with active nephritis: Clinical/pathologic associations and etiologic mechanisms
por: Wither, Joan E., et al.
Publicado: (2018)

A discrete cluster of urinary biomarkers discriminates between active systemic lupus erythematosus patients with and without glomerulonephritis
por: Landolt-Marticorena, Carolina, et al.
Publicado: (2016)

A Novel Inflammatory Dendritic Cell That Is Abundant and Contiguous to T Cells in the Kidneys of Patients With Lupus Nephritis
por: Parikh, Samir V., et al.
Publicado: (2021)

Low-Grade Proteinuria Does Not Exclude Significant Kidney Injury in Lupus Nephritis
por: De Rosa, Marcelo, et al.
Publicado: (2020)

Remission of lupus nephritis: the trajectory of histological response in successfully treated patients
por: Malvar, Ana, et al.
Publicado: (2023)

Creatinine Fluctuation in Patients With Lupus Nephritis: Considerations for Clinical Trial Endpoints
por: Almaani, Salem, et al.
Publicado: (2020)

Expanding the Role of Complement Therapies: The Case for Lupus Nephritis
por: Li, Nicholas L., et al.
Publicado: (2021)

Renal flare as a biomarker of incident and progressive chronic kidney disease in patients with lupus nephritis
por: Parikh, S, et al.
Publicado: (2012)

Unmet medical needs in lupus nephritis: solutions through evidence-based, personalized medicine
por: Anders, Hans-Joachim, et al.
Publicado: (2015)

por: Almaani, Salem, et al.
Publicado: (2020)

Cytokine profiles of lupus patients with or without nephritis
por: Rovin, BH, et al.
Publicado: (2012)

Daratumumab in Patients With Bortezomib-Refractory Proliferative Glomerulonephritis With Monoclonal Immunoglobulin Deposits
por: Almaani, Salem, et al.
Publicado: (2021)

B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial
por: Furie, Richard A, et al.
Publicado: (2022)

Outcome of participants with nephrotic syndrome in combined clinical trials of lupus nephritis
por: Gomez Mendez, Liliana Michelle, et al.
Publicado: (2019)

Limited Reliability of the Spot Urine Protein/Creatinine Ratio in the Longitudinal Evaluation of Patients With Lupus Nephritis
por: Shidham, Ganesh, et al.
Publicado: (2018)

Effect of belimumab on kidney-related outcomes in patients with lupus nephritis: post hoc subgroup analyses of the phase 3 BLISS-LN trial
por: Anders, Hans-Joachim, et al.
Publicado: (2023)

Lupus nephritis is linked to disease-activity associated expansions and immunity to a gut commensal
por: Azzouz, Doua, et al.
Publicado: (2019)

Urinary TWEAK as a biomarker of lupus nephritis: a multicenter cohort study
por: Schwartz, Noa, et al.
Publicado: (2009)

Identification and Validation of a Urinary Biomarker Panel to Accurately Diagnose and Predict Response to Therapy in Lupus Nephritis
por: Whittall-Garcia, Laura, et al.
Publicado: (2022)

Diabetic Kidney Disease: The “Silent” Majority?
por: Yau, Amy, et al.
Publicado: (2021)

Anifrolumab in lupus nephritis: results from second-year extension of a randomised phase II trial
por: Jayne, David, et al.
Publicado: (2023)

A proteinuria cut-off level of 0.7 g/day after 12 months of treatment best predicts long-term renal outcome in lupus nephritis: data from the MAINTAIN Nephritis Trial
por: Tamirou, Farah, et al.
Publicado: (2015)

The Influence of an Elastase-Sensitive Complement C5 Variant on Lupus Nephritis and Its Flare
por: Toy, Chris R., et al.
Publicado: (2021)

Experience with abatacept in refractory lupus nephritis
por: Calatayud, Emma, et al.
Publicado: (2023)

Phase II randomised trial of type I interferon inhibitor anifrolumab in patients with active lupus nephritis
por: Jayne, David, et al.
Publicado: (2022)

Lupus-like nephritis with positive anti-neutrophil cytoplasmic antibodies and negative antinuclear antibodies
por: Santos, Joana Eugénio, et al.
Publicado: (2020)

Establishing a Case for Anti-complement Therapy in Membranous Nephropathy
por: Ayoub, Isabelle, et al.
Publicado: (2020)

Hydralazine-Induced Isolated Lupus Nephritis
por: Khan, Naseer, et al.
Publicado: (2020)

The value of repeat biopsy in lupus nephritis flares
por: Narváez, Javier, et al.
Publicado: (2017)

A Multicenter, Randomized, Double‐Blind, Placebo‐Controlled Study to Evaluate the Efficacy and Safety of Treatment With Sirukumab (CNTO 136) in Patients With Active Lupus Nephritis
por: Rovin, Brad H., et al.
Publicado: (2016)

Identification of Reference Proteins for Western Blot Analyses in Mouse Model Systems of 2,3,7,8-Tetrachlorodibenzo-P-Dioxin (TCDD) Toxicity
por: Prokopec, Stephenie D., et al.
Publicado: (2014)

The Pathogenesis of Lupus Nephritis
por: Sterner, Rosalie M., et al.
Publicado: (2014)

Pediatric lupus nephritis
por: Pinheiro, Sergio Veloso Brant, et al.
Publicado: (2018)

Hyperhomocysteinemia and Lupus Nephritis
por: Timlin, Homa, et al.
Publicado: (2019)

Management of Lupus Nephritis
por: Tamirou, Farah, et al.
Publicado: (2021)

Lupus Nephritis and Dysbiosis
por: Monticolo, Marta, et al.
Publicado: (2023)

Transcriptomic Impact of IMA-08401, a Novel AHR Agonist Resembling Laquinimod, on Rat Liver
por: Prokopec, Stephenie D., et al.
Publicado: (2019)

Patients with Proliferative Lupus Nephritis Have Autoantibodies That React to Moesin and Demonstrate Increased Glomerular Moesin Expression
por: Caster, Dawn J., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_3etetumgcesd9hnbk6ib29sjg3